Composition for preventing or treating hair loss, or promoting hair growth or hair nourishment, comprising as active ingredient decellularized extracellular matrix derived from skin keratinocytes

A decellularized extracellular matrix from skin keratinocytes is used to stimulate hair growth and prevent loss, addressing the limitations of existing treatments by enhancing cell proliferation and gene expression, providing effective hair growth promotion with reduced side effects.

WO2024228415A1PCT designated stage expired Publication Date: 2024-11-07KONKUK UNIV IND COOP CORP

Patent Information

Application Number
PCT/KR2023/006498
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2023-05-12
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current hair loss treatments, such as minoxidil and finasteride, have limited effectiveness and are associated with side effects, and there is a need for a more natural substance with fewer adverse reactions that can promote hair growth and prevent hair loss.

Method used

A composition containing decellularized extracellular matrix derived from skin keratinocytes, which is used to stimulate dermal papilla cells and outer root sheath cells, promoting hair follicle formation and growth cycle regulation, thereby preventing or treating hair loss and promoting hair growth.

Benefits of technology

The composition effectively increases cell proliferation, gene expression, and hair growth, offering improved hair loss prevention and promotion with minimal side effects, comparable to or exceeding the efficacy of existing treatments like minoxidil.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023006498_07112024_PF_FP_ABST
    Figure KR2023006498_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for preventing or treating hair loss, or promoting hair growth or hair nourishment, comprising, as an active ingredient, decellularized extracellular matrix derived from skin keratinocytes. By comprising, as an active ingredient, decellularized extracellular matrix derived from skin keratinocytes, the composition of the present invention significantly promotes the cell proliferation of dermal papilla cells or outer root-sheath cells and increases the expression of genes that regulate hair follicle formation and hair cycle, and thus has an excellent effect of preventing or treating hair loss or on hair growth or hair nourishment. In addition, considering that the dermal papilla cells or the outer root-sheath cells are fibroblasts and keratinocytes of the hair follicle, respectively, the composition of the present invention is expected to be effective not only in hair growth but also in skin wound repair and anti-aging. The decellularized extracellular matrix derived from skin keratinocytes, of the present invention, can be used as a functional ingredient without the risk of immune response and spread of infectious diseases, and is easy to obtain compared to extracellular vesicles or exosomes and can thus be effectively used in medicines, foods, health functional foods, feeds, cosmetics, functional cosmetics, medical devices, and the like.
Need to check novelty before this filing date? Find Prior Art

Description

A composition for preventing or treating hair loss, or for promoting hair growth or hair growth, comprising a decellularized extracellular matrix derived from skin keratinocytes as an active ingredient

[0001] The present invention relates to a composition for preventing or treating hair loss, or for promoting hair growth or hair growth, comprising a decellularized extracellular matrix derived from skin keratinocytes as an effective ingredient.

[0002] In the human body, hair grows from hair follicles in the skin, and the hair follicle, from which hair grows, is a complex organ composed of the inner root epithelial sheath, the outer root epithelial sheath, the hair shaft, and the hair matrix, and is characterized by a cycle of growth, catagen, and telogen that continuously repeats throughout life. In particular, dermal papilla cells, among the cells that form the hair follicle, play an important role in hair growth, and during the anagen phase of the hair follicle, proliferation of cells constituting the hair follicle, including keratinocytes in the matrix surrounding the dermal papilla, occurs. During the catagen phase of the hair follicle, hair follicle growth stops, and apoptosis, condensation of the dermal papilla, and restructuring of the extracellular matrix occur. During the telogen phase, which is the stage in which the hair follicle prepares to enter the anagen phase again, only the permanently lasting part, including the raised area, remains.

[0003] Hair loss refers to an abnormal increase in hair loss due to an increase in the proportion of hair growing from hair follicles in the catagen or resting phase compared to hair growing from hair follicles in the growth phase. Recently, as the emphasis on appearance has become more prominent, interest in hair loss has also increased. The causes of hair loss have been discussed, including poor blood circulation, excessive androgen action, excessive sebum secretion, decreased scalp function due to peroxides and bacteria, genetic factors, aging, stress, etc. However, the exact cause of hair loss is still unknown. In general, the most typical form of hair loss is androgenetic alopecia, which is caused by excessive androgen action, and it occurs dependently on the male hormone androgen. Representative androgens include testosterone and dihydrotestosterone (DHT), and it is known that DHT is more abundant in hair loss patients. Testosterone is converted into DHT by 5-alpha-reductase, and this conversion occurs by Type 2 5-alpha-reductase among the two types of 5-alpha-reductase, Type 1 and Type 2. It has been reported that the converted DHT causes gradual miniaturization of the dermal papilla and hair follicles.

[0004] The most widely used treatment and prevention of this type of hair loss is currently the minoxidil-containing preparation from Upjohn, which has been approved by the U.S. FDA. Recently, Propecia, which contains finasteride, a type 2 5-alpha-reductase inhibitor, has been released and is being used by Merck.

[0005] In addition, research on hair loss treatment or hair growth agent based on natural extracts is also being conducted, and the results include extracts of Cheongung (Patent No. 2010-0119761), Sanghwang mushroom (Patent No. 2012-0038426), Lonicera japonica (Patent No. 2012-0038426), chamomile (Patent No. 2012-0015874, Patent No. 2010-0091571), Hosuo (Patent No. 2013-0021464, Patent No. 2011-0097386), Changpo (Patent No. 2012-0115980), pomegranate (Patent No. 2012-7012465), and ginkgo leaf extract (Patent No. 2006-7008793). Additionally, red fruits and vegetables are known to have excellent antioxidant effects and are effective in treating hair loss symptoms, so development of hair growth products using red fruits and vegetables is also being promoted.

[0006] However, since the effects of these hair growth agents or hair tonics on the scalp when actually used in clinical practice were not that outstanding, research is actively being conducted to find hair growth agents made of natural substances that are more effective and have fewer side effects than minoxidil or propecia, which are often avoided due to concerns about side effects.

[0007] Meanwhile, extracellular matrix (ECM) can be divided into tissue-derived ECM and cell-derived ECM. Tissue-derived ECM has been commercialized as a variety of medical devices, and cell-derived ECM has been reported in the literature to exhibit regenerative efficacy in various tissues and organs.

[0008] Accordingly, the inventors of the present invention have conducted extensive research efforts to develop a hair growth agent with excellent efficacy using ECM, a natural substance with few side effects, and as a result, they have confirmed that ECM obtained by culturing HaCaT cells (skin keratinocytes) and then undergoing a decellularization process increases the number of dermal papilla cells (HDP) and outer root-sheath cells (ORS) that constitute hair follicles, and increases the expression of genes that regulate hair follicle formation and the hair growth cycle, thereby exhibiting excellent hair loss improvement and hair growth promotion effects, thereby completing the present invention.

[0009] Numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety to provide a clearer understanding of the state of the art and the scope of the present invention.

[0010] The purpose of the present invention is to provide a cosmetic composition for preventing or improving hair loss, or for promoting hair growth or hair growth, which contains a decellularized extracellular matrix derived from skin keratinocytes as an active ingredient and has excellent hair loss prevention, improvement, or treatment effects, or hair growth or hair growth effects while having few side effects; a pharmaceutical composition for preventing or treating hair loss, or for promoting hair growth or hair growth; a quasi-drug composition for preventing or improving hair loss, or for promoting hair growth or hair growth; a health functional food composition for preventing or improving hair loss, or for promoting hair growth or hair growth; and a feed composition for preventing or improving hair loss, or for promoting hair growth or hair growth.

[0011] In addition, another object of the present invention is to provide a composition for skin wound repair comprising a decellularized extracellular matrix derived from skin keratinocytes as an active ingredient.

[0012] In addition, another object of the present invention is to provide an anti-aging composition comprising a decellularized extracellular matrix derived from skin keratinocytes as an effective ingredient.

[0013] In order to achieve the above-mentioned purpose, the present invention provides a cosmetic composition for preventing or improving hair loss, or for promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an effective ingredient.

[0014] In one embodiment of the present invention, the decellularized extracellular matrix may be obtained from cells cultured in vitro.

[0015] In one embodiment of the present invention, the decellularized extracellular matrix may induce hair growth by activating dermal papilla cells (DPCs).

[0016] In one embodiment of the present invention, the cosmetic composition may contain 0.001 to 10.0 (w / v)% of the decellularized cells and extracellular matrix.

[0017] In one embodiment of the present invention, the cosmetic composition may have a formulation of hair tonic, hair lotion, hair oil, hair shampoo, hair rinse, hair conditioner, hair treatment, hair cream, hair pack, hair spray, hair essence, hair mousse or hair gel.

[0018] In order to achieve the above-mentioned other objects, the present invention provides a pharmaceutical composition for preventing or treating hair loss, or for promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

[0019] In one embodiment of the present invention, the pharmaceutical composition may have a formulation of an injection, an infusion, a spray, a liquid, or a patch.

[0020] In one embodiment of the present invention, it may be administered transdermally by topical application to the scalp of a mammal, microneedling, injection, or a combination thereof.

[0021] In order to achieve another object mentioned above, the present invention provides a pharmaceutical composition for preventing or improving hair loss, or promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an effective ingredient.

[0022] In order to achieve another object described above, the present invention provides a health functional food composition for preventing or improving hair loss or promoting hair growth or hair growth, which contains a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an effective ingredient.

[0023] In order to achieve another object described above, the present invention provides a feed composition for preventing or improving hair loss, or promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an effective ingredient.

[0024] The composition of the present invention significantly promotes cell proliferation of hair papilla cells or hair root sheath cells by including a decellularized extracellular matrix derived from skin keratinocytes as an effective ingredient, and increases the expression of genes that regulate hair follicle formation and the hair growth cycle, and thus has an excellent effect in preventing or treating hair loss or in hair growth or hair restoration.

[0025] In addition, considering that the hair papilla cells or hair root sheath cells are fibroblasts and keratinocytes of the hair follicle, respectively, the composition of the present invention is expected to be effective not only for hair growth but also for skin wound repair and anti-aging.

[0026] The decellularized extracellular matrix derived from skin keratinocytes of the present invention can be used as a functional material without the risk of immune response and transmission of infectious diseases, and is easier to obtain than extracellular vesicles or exosomes, so that it can be usefully used in pharmaceuticals, foods, health functional foods, cosmetics, functional cosmetics, and medical devices.

[0027] Figure 1 shows that when human hair papilla cells (HDP cells) of hair follicles were cultured in 3D (spheroid) using an aggrewell plate and then treated with decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes according to an embodiment of the invention, the diameter of the HDP cell spheroids (Figures 1a and 1b) increased and the genomic DNA concentration (Figure 1c) increased.

[0028] Figure 2 shows the results of analyzing gene expression by multiplex RT-PCR for cell samples on the 7th day of spheroid culture of HDP cells of hair follicles, and shows that when decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes according to an embodiment of the present invention was treated, the expression of signature genes of HDP cells increased or was similar to that of the positive control group treated with minoxidil.

[0029] Figure 3 shows the results of immunocytochemical staining confirming that when HDP cells of hair follicles were cultured into spheroids and then treated with decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes according to an embodiment of the present invention, the expression of β-catenin and Sox 2, which are involved in the proliferation and differentiation of HDP cells, increased compared to the minoxidil treatment group, which is a positive control group.

[0030] FIG. 4 shows the results of confirming that when the decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes according to an embodiment of the present invention was treated after spheroid culture of HDP cells of hair follicles, the expression of 5α-reductase involved in androgenetic alopecia in HDP cells was reduced compared to the positive control group of minoxidil treatment group and finasteride treatment group.

[0031] Figure 5 is a CCK-8 analysis result showing that when the decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes according to an embodiment of the present invention was treated at a concentration of 1 μg / ml to hair root sheath cells (ORS cells), the number of cells increased compared to the positive control group treated with minoxidil (1 μM or 10 μM).

[0032] Figure 6 shows that when the decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes according to an embodiment of the present invention was treated to ORS cells of the hair follicle, proliferation and differentiation of hair root sheath cells increased compared to the minoxidil treatment group, which is a positive control group. Specifically, it is an immunocytochemical staining result showing that the expression of ALP (ORS cell proliferation and hair cycle regulation) (Figure 6a), SOX9 (hair cycle regulation and hair follicle stem cell formation) (Figure 6b), and β-catenin (hair cycle regulation and hair follicle formation) (Figure 6c) all increased.

[0033] Figure 7 shows the results of comparing cell migration ability over time after scratching HDF cells and treating them with decellularized extracellular matrix derived from skin keratinocytes (HaCaT_ECM) and decellularized extracellular matrix derived from skin fibroblasts (HDF_ECM) according to an example.

[0034] Figure 8 shows the results of multiplex RT-PCR performed after treating HDF cells with decellularized extracellular matrix derived from skin keratinocytes (HaCaT_ECM) and decellularized extracellular matrix derived from skin fibroblasts (HDF_ECM) according to an embodiment of the present invention, and the expression of mRNA of FGF2, TGFB2, and COL3A1 in HDF treated with HaCaT_ECM was significantly increased compared to the control and HDF_ECM treated groups.

[0035] Figure 9 shows the results of performing human growth factor antibody array membrane analysis after treating HDF cells with decellularized extracellular matrix derived from skin keratinocytes (HaCaT_ECM) and decellularized extracellular matrix derived from skin fibroblasts (HDF_ECM) according to an embodiment of the present invention, and the expression of growth factor proteins such as bNGF and PDGF-BB in HDF treated with HaCaT_ECM increased compared to the control and HDF_ECM treated groups.

[0036] Figure 10 shows the results of analyzing gene expression by multiplex RT-PCR for cell samples on the 7th day of spheroid culture of HDP cells, showing that when decellularized extracellular matrix derived from skin keratinocytes (HaCaT_ECM) according to an example of the present invention was treated, the expression of signature genes of HDP cells significantly increased compared to the control group (Con) and the group treated with decellularized extracellular matrix derived from skin fibroblasts (HDF_ECM).

[0037] Fig. 11 shows the results of evaluating the hair growth improvement efficacy by comparing the group treated with 0.1% of the decellularized extracellular matrix (HaCaT_ECM) derived from keratinocytes according to an embodiment of the present invention and the positive control group treated with 3% minoxidil after shaving and removing the hair on the back of a male C57Bl / 6 mouse using a hair removal cream to induce hair cycle synchronization. Fig. 11a is a photograph comparing the degree of hair growth on Day 0, Day 5, Day 7, and Day 14 after treating the decellularized extracellular matrix (HaCaT_ECM) of the present invention on the back skin of the depilated mouse with the positive control group treated with minoxidil, and Fig. 11b is a microscopic observation result confirming that no side effect of hyperkeratosis of the mouse back skin on Day 14 occurred, and Fig. 11c is a graph showing the number of hair follicles corresponding to each hair cycle for tissues collected from the mouse back skin on Day 14.

[0038] In the present invention, the term “decellularization” means removing cellular components other than the extracellular matrix, such as the nucleus, cell membrane, nucleic acids, etc., from a cell or tissue.

[0039] The term “extracellular matrix” in the present invention refers to a macromolecular network with a non-cellular three-dimensional structure, composed of collagen, proteoglycans / glycosaminoglycans, elastin, fibronectin, laminin, glycoproteins, etc., and forms a complex structure with cells in all tissues and organs, and each component or cell adhesion receptor is bound to each other. In addition, various receptors present on the cell surface also play a role in transmitting signals such as survival, growth, migration, differentiation, etc. from the extracellular matrix to the cells.

[0040] As used herein, the term "decellularized extracellular matrix" refers to the extracellular matrix remaining after cellular components such as the nucleus, cell membrane, and nucleic acids have been removed from a tissue or cell. The decellularized extracellular matrix is ​​obtained by removing only the nucleus and cell membrane from a cell population, thereby allowing the utilization of all of the extracellular matrix components.

[0041] In addition, the decellularized extracellular matrix of the present invention may be obtained from cells cultured in vitro. After culturing keratinocytes in vitro, the cultured cell population is decellularized, and the resulting extracellular matrix can be utilized in the composition for preventing, improving, or treating hair loss, or for promoting hair growth or hair growth of the present invention. That is, it may be more preferable in terms of efficacy to utilize the extracellular matrix obtained by culturing keratinocytes in vitro, then decellularizing the cultured cell population, for preventing, improving, or treating hair loss, or for promoting hair growth or hair growth, than the extracellular matrix derived from skin tissue formed within a subject. In addition, when the decellularized extracellular matrix is ​​obtained from cells cultured in vitro, the supply problem, which is a disadvantage of tissue-derived extracellular matrix, can be solved, and since autologous cells can be used, the possibility of an immune rejection reaction is low.

[0042] In the present invention, the term “hair loss” refers to a phenomenon in which hair completely falls out of the scalp.

[0043] In the present invention, the term “hair growth” means hair growing from the scalp.

[0044] In the present invention, the term “hair growth” means that the length of hair increases or the thickness increases, and is used with the same meaning as “wool,” another term used in the art.

[0045] The term "dermal papilla cells" used in the present invention refers to cells present at the base of the hair follicle, which supply oxygen and nutrients to the cells that make up the hair follicle, thereby regulating hair growth and the hair follicle cycle. Therefore, promoting the proliferation of dermal papilla cells can promote healthy hair, promote hair growth, and prevent hair loss. Hair growth occurs when the epithelial cells surrounding the dermal papilla divide to form the hair shaft, and therefore dermal papilla cells play a crucial role in regulating the division of these epithelial cells.

[0046] In the present invention, the term "outer root sheath cell" specifically refers to the outer root sheath, and corresponds to keratinocytes (i.e., scalp cells) of the hair follicle. The outer root sheath cell is the cell that forms the basis of hair, and when the proliferation of the outer root sheath cell is promoted, hair growth is promoted and hair loss can be prevented.

[0047] In the present invention, the term “hair growth cycle” is also called the hair cycle, and is divided into the growth phase (anagen, growing phase) in which hair is expressed as stem cells and grows, the transitional phase (catagen, regression phase) in which blood vessels decline, and the resting phase (telogen, resting phase) in which growth stops and hair falls out due to complete cessation of nutrient supply. This cycle repeats over 3 to 6 years, and normally, an average of 50 to 100 hairs fall out per day. The reasons for alopecia, or the absence of hair, or the appearance of a bald spot, are various, and may include hormonal, immune, aging, and genetic problems, but the bottom line is that many hair follicles fail to transition to the growth phase and remain in the resting phase.

[0048]

[0049] Hereinafter, the present invention will be described in detail.

[0050] One aspect of the present invention relates to a cosmetic composition for preventing or improving hair loss or promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

[0051] In the present invention, the term “prevention” means reducing the risk of contracting a disease or disorder, and means any act of inhibiting or delaying the onset of a disease by preventing the progression of one or more clinical symptoms of the disease in a subject who is exposed to or susceptible to the disease but has not yet contracted the disease or shown symptoms of the disease.

[0052] In the present invention, the term “improvement” means any act that improves or benefits the symptoms of a disease or disorder.

[0053] The above prevention or improvement of hair loss may be achieved by removing the cause of hair loss or inhibiting the progression of hair loss, or by inhibiting hair loss or promoting hair formation to promote hair growth or hair growth.

[0054] In one embodiment, the decellularized extracellular matrix may be obtained from cells cultured in vitro.

[0055] In one embodiment, the decellularization method for obtaining the decellularized extracellular matrix can be performed by a known method or an appropriate modification thereof. The decellularization method is intended to remove the remaining cellular components except for the extracellular matrix, and may use a physical method, a chemical method, or a mixed method thereof, and specifically, a chemical method may be used. The chemical method may be a process of immersing cultured cells in a decellularization solution for a certain period of time. The decellularization solution may be an acidic solution, an alkaline solution, a non-ionic detergent, or an ionic detergent, but is preferably a non-ionic detergent.

[0056] More specifically, the decellularization method may be a method of removing intracellular components by breaking the cell membrane using a nonionic detergent, such as Triton X-100. In addition, the decellularization method may be a method of removing nuclear components by additionally using DNase and RNase.

[0057] In the following examples, the cell membrane of a population of skin keratinocytes cultured in vitro was broken using a non-ionic detergent, Triton X-100, to remove intracellular components, and then DNase and RNase were used to remove nuclear components to prepare a decellularized extracellular matrix.

[0058] The above-described decellularized extracellular matrix removes only the nucleus and cell membrane from a cell population, allowing the entire extracellular matrix component to be utilized, thereby providing a more natural, biomimetic microenvironment for cell growth and differentiation. Furthermore, the extracellular matrix thus obtained has a structure in which nano- or micro-sized fiber bundles are formed in a consistent pattern. The extracellular matrix contains various proteins necessary for cell adhesion and cell signaling, as well as growth factors and cytokines essential for regulating stem cell differentiation.

[0059] In one embodiment, the decellularized extracellular matrix may be obtained by a method comprising: a step of culturing skin keratinocytes as a cell population; a step of primary decellularization by adding a solution containing a nonionic surfactant to the cell population; and a step of secondary decellularization by adding DNase and RNase A to the solution in which the primary decellularization is completed.

[0060] The decellularized extracellular matrix of the present invention obtained by the above method has the activity of promoting the proliferation of hair papilla cells and hair root sheath cells, etc., and regulating the hair growth cycle to promote hair growth or hair growth.

[0061] In the following examples, when the decellularized extracellular matrix of the present invention was applied to hair papilla cells and / or hair root sheath cells, the proliferation of the hair papilla cells and / or hair root sheath cells and the expression of genes related to the hair growth cycle were promoted, and in particular, it was confirmed that the decellularized extracellular matrix derived from skin keratinocytes had a hair growth effect similar to or superior to that of minoxidil, which is commercially available as a hair loss treatment agent. Therefore, it was first clarified that the decellularized extracellular matrix derived from skin keratinocytes can be used for the purpose of preventing or improving hair loss, or promoting hair growth or hair growth.

[0062] In one embodiment, the decellularized extracellular matrix of the present invention may induce hair growth by activating dermal papilla cells (DPCs) and / or outer root sheath cells (ORS).

[0063] The cosmetic composition of the present invention may contain the decellularized extracellular matrix in an amount of 0.001 to 10.0 (w / v)%, preferably 0.01 to 5.0 (w / v)%, more preferably 0.05 to 2.0 (w / v)%, and even more preferably 0.05 to 1.0 (w / v)%. When the concentration of the decellularized extracellular matrix contained in the composition of the present invention is within the above range, the decellularized extracellular matrix has the advantage of sufficiently exhibiting the hair loss prevention and / or hair growth promotion effect, while not exhibiting toxicity or side effects to a living organism or its cells. When the content of the decellularized extracellular matrix of the present invention contained in the composition is less than the lower limit, the hair loss prevention and / or hair growth promotion effect becomes minimal, and when it exceeds the upper limit, there is a problem in the safety and stability of the formulation, and it is not economical.

[0064] Additionally, the cosmetic composition of the present invention may include a cosmetically acceptable carrier. Specifically, the carrier may be a compound or composition already known and used that does not exhibit toxicity, instability, or irritation beyond what the human body can tolerate when in contact with the skin, and may be generally included in cosmetic compositions.

[0065] Examples of the above carrier include alcohol, oil, surfactant, fatty acid, silicone oil, humectant, moisturizer, thickener, pH adjuster, solubilizer, preservative, emulsion, stabilizer, ultraviolet scattering agent, ultraviolet absorber, color developer, fragrance, etc. Compounds / compositions that can be used as the above alcohol, oil, surfactant, fatty acid, silicone oil, humectant, moisturizer, thickener, pH adjuster, solubilizer, preservative, emulsion, stabilizer, ultraviolet scattering agent, ultraviolet absorber, color developer, fragrance, etc. are already known in the art, so that a person skilled in the art can select and use an appropriate corresponding substance / composition.

[0066] In one specific example, the thickener serves to maintain stability against temperature and pH changes and adhesion to the scalp after spraying, and for example, the thickener may be at least one selected from the group consisting of carbomer, cetyl hydroxyethyl cellulose, poloxamer, xanthan gum, carrageenan gum, locust bean gum, gellan gum, polyacrylic acid, PAA, PAAc, Acrysol, Acumer, alcosperse, Aquatreat, and Sokalan, but is not limited thereto. For example, the thickener may be carbomer, and has the advantage of having a thickening effect in a wide pH range, being able to thicken very transparently, and having an excellent thickening effect even at a low concentration. In addition, it is safe for microorganisms, has no toxicity or irritation, and has the advantage of not having a viscosity change depending on temperature.

[0067] Additionally, pH regulators are used to stabilize the formulation of cosmetics and relieve scalp irritation, and when used together with carbomer, they can neutralize the acidity of carbomer, contributing to skin safety. For example, the pH adjusting agent may be triethanolamine, tartaric acid, sodium silicate, sodium hydroxide, sodium citrate, sodium carbonate, sodium borate, sebacic acid, potassium hydroxide, phosphoric acid, malic acid, magnesium hydroxide, magnesium carbonate, lactobionic acid, lactic acid, glycolic acid, gamma linolenic acid, fumaric acid, diethanolamine, citric acid, borate, It may be at least one selected from the group consisting of benzoic acid, azelaic acid, ascorbic acid, aminomethyl propanol, and acetic acid, but is not limited thereto.

[0068] In addition, the preservative plays a role in inhibiting deterioration and decay of the cosmetic composition, and examples thereof include phenoxyethanol, triclosan, sodium sulfite, sodium salicylate, sodium metabisulfite, sodium hydroxymethylglycinate, sodium dehydroacetate, sodium citrate, sodium borate, sodium benzoate, quaternium-15, propylparaben, phytosphingosine, parabens, octyldodecyl neopentanoate, nitrosamines, It may be at least one selected from the group consisting of methylparaben, methylisothiazolinone, methyldibromo glutaronitrile, methylchloroisothiazolinone, isobutylparaben, iodopropynyl butylcarbamate, imidazolidinyl urea, diazolidinyl urea, chlorphenesin, chlorophene, chlorhexidine, butylparaben, benzyl alcohol, benzoic acid, and benzalkonium chloride, but is not limited thereto.

[0069] In addition, the solubilizer plays a role in evenly mixing the particles and the aqueous layer that disperses the particles, and examples thereof include PEG-60 hydrogenated castor oil, Glyceryl Caprylate, Glyceryl Stearate, Hydroxystearyl Glucoside, Stearyl Alcohol, Stearates, Sorbitan Stearate, Sodium Trideceth Sulfate, Potassium Myristate, Potassium Cetyl Phosphate, Polyglyceryl-3 Methyl Glucose Distearate, Polyglyceryl-2 Caprate, It may be at least one selected from the group consisting of phosphatidylcholine, pectin, almitic acid, octyldodecanol, linoleamidopropyl PG-dimonium chloride phosphate, isohexadecane, hydroxylated lecithin, hydroxyethylcellulose, glyceryl myristate, and glyceryl isostearate, but is not limited thereto.

[0070] In addition, the fragrance provides an aromatherapy-like effect for stress relief while also playing a role in stabilizing the scalp. For example, the fragrance may be at least one selected from the group consisting of menthol, lavender oil, bisabolol, sorbitol, and rose hip oil, but is not limited thereto.

[0071] In addition, the cosmetic composition of the present invention can be manufactured in various forms, for example, it can be manufactured as a toner, essence, gel, emulsion, lotion, cream (oil-in-water, water-in-oil, multiphase), solution, suspension (anhydrous and aqueous), anhydrous product (oil and glycol), pack or powder.

[0072] In particular, the cosmetic composition can be manufactured in the form of a general emulsified formulation and a solubilized formulation using a commonly known manufacturing method in addition to the manufacturing method specifically disclosed in the present invention.

[0073] When formulated as cosmetic compositions, emulsified cosmetics include nourishing toners, creams, and essences, while soluble cosmetics include emollient toners. Furthermore, they can be formulated as supplements for topical or general application, typically applied to a portion or the entire scalp.

[0074] In addition, suitable cosmetic formulations may be provided in the form of solutions, gels, solid or paste anhydrous products, emulsions obtained by dispersing oil in water, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) or non-ionic vesicular dispersions, creams, skin lotions, powders, ointments, sprays or concealers. In addition, they may be prepared in the form of foams or in the form of aerosol compositions further containing compressed propellants.

[0075] As a specific formulation, the cosmetic composition of the present invention can be prepared in the form of a hair tonic, hair lotion, hair oil, hair shampoo, hair rinse, hair conditioner, hair treatment, hair cream, hair pack, hair spray, hair essence, hair mousse or hair gel.

[0076]

[0077] Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating hair loss, or for promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

[0078] In addition, the present invention relates to a pharmaceutical composition for animals for preventing or treating hair loss or promoting hair growth or hair growth, which comprises a decellularized extracellular matrix derived from skin keratinocytes as an effective ingredient.

[0079] Since the “decellularized extracellular matrix derived from skin keratinocytes”, “hair loss”, “hair growth” and “hair restoration” of the present invention have already been described above, their descriptions are omitted to avoid excessive duplication.

[0080] In the present invention, the term “treatment” means alleviating a disease or disorder, and includes all acts that improve or beneficially change the symptoms of a disease by preventing or reducing the progression of the disease or one or more of its clinical symptoms.

[0081] In the pharmaceutical composition of the present invention, the decellularized extracellular matrix may be included in a therapeutically effective amount, and may further include a pharmaceutically acceptable carrier. The term "therapeutically effective amount" refers to an amount sufficient to achieve the purpose of the composition, which is to prevent or treat hair loss.

[0082] In the present invention, hair loss means the absence of hair in an area where hair should normally exist, and includes a phenomenon in which the number of hairs decreases compared to the normal state. The hair loss is a concept that includes both non-scarring hair loss and scarring hair loss depending on whether hair follicles are destroyed, and includes, for example, hereditary androgenetic alopecia, alopecia areata, tinea capitis caused by fungal infection, telogen effluvium, trichotillomania, hair growth disorder disease, hair loss caused by lupus, folliculitis fulminans, lichen planus pilaris, hair loss caused by burns and / or trauma, hair loss of unknown cause such as alopecia X, idiopathic hair loss, etc.

[0083] The above prevention or treatment of hair loss may be to eliminate the cause of hair loss as described above or to suppress the progression of hair loss, or to promote hair growth by suppressing hair loss or promoting hair formation.

[0084] Meanwhile, the “pharmaceutical composition”, “medicine”, “veterinary pharmaceutical composition” or “veterinary medicine” of the present invention can be manufactured in the form of a unit dose by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains, or can be manufactured by inserting it into a multi-dose container. At this time, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablets, capsules or gel (e.g., hydrogel), and may additionally include a dispersant or stabilizer.

[0085] Additionally, the decellularized extracellular matrix contained in the composition may be delivered in a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline solution, lipids, liposomes, microspheres, or nano-spheres. These may be complexed or associated with a carrier, and may be delivered in vivo using carrier systems known in the art, such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancing substances, or fatty acids.

[0086] In addition, the pharmaceutically acceptable carrier may include, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, which are commonly used in formulations. In addition, in addition to the above ingredients, the pharmaceutical composition may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.

[0087] The composition according to the present invention can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical preparation. That is, the composition of the present invention can be administered in various oral and parenteral dosage forms during actual clinical administration. When formulated, it is prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases can include withepsol, macrogol, Tween 61, cacao butter, laurin butter, glycerol, and gelatin.

[0088] In one specific example, the pharmaceutical composition, medicament, veterinary pharmaceutical composition or veterinary medicament may be prepared in the form of an injection, ointment, infusion, spray, liquid or patch.

[0089] The composition may be administered transdermally by topical application to the scalp of a mammal, microneedling, injection, or a combination thereof.

[0090] The term "injection" in the present invention refers to the use of a syringe to inject a medicinal solution into the skin, subcutaneously, intramuscularly, intravenously, or intraarterially. Specifically, given the characteristics of the pharmaceutical composition of the present invention exhibiting hair loss prevention or hair growth promotion effects, the injection may be subcutaneous, but is not limited thereto. The syringe may be any syringe capable of administering a medicinal solution through a needle, as well as any syringe used for subcutaneously administering the pharmaceutical composition of the present invention, without limitation.

[0091] The amount of the active ingredient included in the composition of the present invention varies depending on the condition of the subject to be administered, the degree of treatment desired, etc. Specifically, the decellularized extracellular matrix of the present invention may be included in the pharmaceutical composition at a concentration of 0.001 to 10 (w / v)%, preferably 0.01 to 5 (w / v)%, and more preferably 0.05 to 2 (w / v)%.

[0092] If the concentration of the decellularized extracellular matrix is ​​below the lower limit, the hair loss prevention or hair growth promotion effect of the composition may be minimal, and if it exceeds the upper limit, there is a problem that side effects may occur in the body.

[0093] Additionally, the composition of the present invention may additionally include a penetration enhancer.

[0094] The above percutaneous absorption promoter may be at least one selected from sulfoxide, azone, pyrrolidone, fatty acid, lower alcohol having 1 to 4 carbon atoms, higher fatty alcohol having 6 or more carbon atoms, glycol, urea, terpene, terpenoid, and phospholipid. However, the present invention is not limited thereto, and may include conventional promoters used in pharmaceutical compositions to promote percutaneous absorption of active ingredients.

[0095] In addition, the dosage of the pharmaceutical composition, medicine, veterinary pharmaceutical composition or veterinary medicine may vary depending on factors such as the formulation method, administration method, patient's age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and response sensitivity, but may be 0.0001 to 200 mg / kg, preferably 0.0001 to 100 mg / kg, more preferably 0.001 to 100 mg / kg, more preferably 0.01 to 100 mg / kg, more preferably 0.1 to 50 mg / kg based on the daily dosage, and may be administered in divided doses several times a day at regular time intervals, preferably 2 to 3 times a day, according to the judgment of a doctor or pharmacist.

[0096]

[0097] Another aspect of the present invention relates to a pharmaceutical composition for preventing or improving hair loss or promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

[0098] Since the “decellularized extracellular matrix derived from skin keratinocytes”, “hair loss”, “hair growth” and “hair restoration” of the present invention have already been described above, their descriptions are omitted to avoid excessive duplication.

[0099] In the present invention, the term “quasi-drug” means a product that has a milder effect than a pharmaceutical product among products used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases of humans or animals. For example, according to the Pharmaceutical Affairs Act of the Republic of Korea, a quasi-drug is a product excluding products used for the purpose of pharmaceutical products, and includes products used for treating or preventing diseases of humans or animals, products that have a mild effect on the human body or do not act directly, etc.

[0100] The pharmaceutical composition of the present invention can be manufactured in a form selected from the group consisting of body cleanser, foam, soap, mask, ointment, cream, lotion, essence, and spray, but is not limited thereto.

[0101] When using a composition containing the decellularized extracellular matrix of the present invention as an active ingredient as an over-the-counter drug additive, the composition containing the decellularized extracellular matrix of the present invention may be added as is or used together with other over-the-counter drugs or over-the-counter drug ingredients, and may be used appropriately according to a conventional method.

[0102]

[0103] Another aspect of the present invention relates to a health functional food composition for preventing or improving hair loss or promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

[0104] Since the “decellularized extracellular matrix derived from skin keratinocytes”, “hair loss”, “hair growth” and “hair restoration” of the present invention have already been described above, their descriptions are omitted to avoid excessive duplication.

[0105] The “food composition” of the present invention may include, in addition to the decellularized extracellular matrix as an active ingredient, food raw materials usable as food described in the standards and specifications for food commonly used in food manufacturing (“Food Code”), and food additives described in the Food Additive Code.

[0106] The food composition described above is not particularly limited, but may include, for example, carbohydrates and flavoring agents. The carbohydrates may include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, lactose, etc.; oligosaccharides or polysaccharides such as dextrin, corn syrup, cyclodextrin, etc.; and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The flavoring agents may include natural flavoring agents [thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.)] and synthetic flavoring agents (saccharin, aspartame, etc.).

[0107] When manufacturing a food composition using the above decellularized extracellular matrix as an effective ingredient, the effective ingredient does not need to be particularly limited as long as it has an effect of preventing or improving hair loss, or promoting hair growth or hair growth. However, for example, it may be included in an amount of 0.001 to 10.0 (w / v)%, preferably 0.01 to 5.0 (w / v)%, more preferably 0.05 to 2.0 (w / v)%, and even more preferably 0.05 to 1.0 (w / v)%.

[0108] In the above food composition, the decellularized extracellular matrix derived from skin keratinocytes, which is an active ingredient, may vary depending on the condition, weight, presence or severity of the disease, and duration of the ingestion, but may be appropriately selected by a person skilled in the art. For example, based on the daily dosage, it may be 0.0001 to 200 mg / kg, preferably 0.0001 to 100 mg / kg, more preferably 0.001 to 100 mg / kg, more preferably 0.01 to 100 mg / kg, and even more preferably 0.1 to 50 mg / kg. The number of administrations need not be particularly limited, but may be adjusted by a person skilled in the art within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or health control, the dosage may be below the above range.

[0109] The above food composition need not be particularly limited, but may be, for example, a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation, or beverage formulation.

[0110] In addition, the decellularized extracellular matrix may be added to general foods to provide hair loss prevention or improvement, or hair growth or hair growth promotion functionality. The foods to which it can be added need not be particularly limited, but for example, it may be added to confectionery, bread or rice cakes, cocoa products or chocolates, meat or egg products, fish products, tofu or jelly products, noodles, teas, coffee, beverages, special-purpose foods, soy sauces, seasoned foods, dressings, kimchi, salted seafood, pickled foods, stewed foods, alcoholic beverages, dried foods, and other foods exemplified in the standards and ingredient specifications for livestock products exemplified in Article 4 of the Livestock Products Sanitation Management Act (“Livestock Products Codex”). In addition, it may be added to dairy products, processed meat products, packaged meat products, and processed egg products exemplified in the processing standards and ingredient specifications for livestock products exemplified in Article 4 of the Livestock Products Sanitation Management Act (“Livestock Products Codex”).

[0111] Meanwhile, a food composition containing the above-described decellularized extracellular matrix as an active ingredient can be used as a health functional food for improving bone health, more specifically, as a health functional food for preventing or improving hair loss, or promoting hair growth or hair growth.

[0112] The above “health functional food” refers to a food manufactured (including processed) in accordance with legal standards using raw materials or ingredients with beneficial functions for the human body (Article 3, Paragraph 1 of the Health Functional Food Act). The terminology and scope of the above “health functional food” may vary by country, but may include “dietary supplements” in the United States, “food supplements” in Europe, “health functional foods” or “foods for special health use (FoSHU)” in Japan, and “health foods” in China.

[0113] The above food composition or health functional food may additionally contain food additives, and its suitability as a food additive shall be determined in accordance with the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the “Food Additives Code” unless otherwise provided.

[0114]

[0115] Another aspect of the present invention relates to a feed composition for preventing or improving hair loss, or for promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

[0116] Since the “decellularized extracellular matrix derived from skin keratinocytes”, “hair loss”, “hair growth” and “hair restoration” of the present invention have already been described above, their descriptions are omitted to avoid excessive duplication.

[0117] The above “feed composition” may use, in addition to the decellularized extracellular matrix derived from skin keratinocytes as an active ingredient, food raw materials usable as food as described in the Food Standards and Specifications (“Food Code”) and food additives as described in the Food Additives Code, and even if they are not food raw materials or food additives usable as food, raw materials falling within the scope of single feed in Appendix 1 of the “Standards and Specifications for Feed, etc.” and raw materials falling within the scope of supplementary feed in Appendix 2 may be used.

[0118] The above “feed composition” may be an extractant among supplementary feeds according to the “Standards and Specifications for Feed, etc.”, and may be a compound feed containing the supplementary feed.

[0119] When preparing the above feed composition, the decellularized extracellular matrix does not need to be particularly limited as long as it has an effect of preventing hair loss or promoting hair growth or hair growth, but may be included in an amount of, for example, 0.001 to 10.0 (w / v)%, preferably 0.01 to 5.0 (w / v)%, more preferably 0.05 to 2.0 (w / v)%, and even more preferably 0.05 to 1.0 (w / v)%.

[0120] In the above feed composition, the decellularized extracellular matrix derived from skin keratinocytes, which is an effective ingredient, may vary depending on the condition, weight, presence or severity of disease, and duration of the ingesting animal, but may be appropriately selected by a person skilled in the art. For example, based on the daily dosage, it may be 0.0001 to 200 mg / kg, preferably 0.0001 to 100 mg / kg, more preferably 0.001 to 100 mg / kg, more preferably 0.01 to 100 mg / kg, and even more preferably 0.1 to 50 mg / kg. The number of administrations need not be particularly limited, but may be adjusted by a person skilled in the art within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or health control, the dosage may be below the above range.

[0121]

[0122] Another aspect of the present invention relates to a method for preventing hair loss or promoting hair growth or hair growth, comprising the steps of: preparing a pharmaceutical composition comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient; and administering the pharmaceutical composition to a subject.

[0123] Since the “decellularized extracellular matrix derived from skin keratinocytes”, “hair loss”, “hair growth” and “hair restoration” of the present invention have already been described above, their descriptions are omitted to avoid excessive duplication.

[0124] The above “administration” means introducing a given substance into an object by an appropriate method, and may preferably be administration into the dermal layer or subcutaneous tissue.

[0125] The above "subject" refers to any animal, including humans, dogs, cats, rats, livestock, etc., that has or may develop hair loss symptoms. Specifically, it may be a mammal, including humans.

[0126]

[0127] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0128]

[0129] <Example>

[0130] In the present invention, a decellularized extracellular matrix (HaCaT_ECM) derived from human keratinocytes was prepared and its effects on human dermal papilla cells and hair root sheath cells were analyzed. The decellularized extracellular matrix derived from human keratinocytes developed in the present invention was confirmed through specific experiments to increase the diameter of dermal papilla cells, promote the proliferation of dermal papilla cells and hair root sheath cells, and increase the differentiation of hair root sheath cells (see Figures 1 to 7).

[0131] Example: Preparation of HaCaT_ECM

[0132] (1) HaCaT cells were cultured in a T-175 flask in complete medium containing 10% fetal bovine serum and 1% antibiotics in DMEM medium for 5 to 7 days to reach 100% confluency.

[0133] (2) After washing the cells with phosphate-buffered saline (PBS), they were decellularized by reacting with a mixed solution of 0.25% Triton X-100 and 10 nM NH4OH at 37°C for 1 minute.

[0134] (3) Afterwards, 50 U / mL DNase and RNase A were added and reacted for 1 hour to remove genetic material.

[0135] (4) The extracellular matrix generated above was washed with PBS, and the final product was freeze-dried at -80°C to produce a decellularized extracellular matrix derived from skin keratinocytes (HaCaT_ECM).

[0136]

[0137] <Example of an exam>

[0138] Culture of human mammary papilla cells

[0139] Human dermal papilla cells (HDP cells) are commonly used as primary cells, and recently, immortalized cell lines transfected with human telomerase transcriptase (hTERT) have become available. Therefore, hTERT-HDP cells were used in this experiment. The dermal papilla cells were cultured in Prigrow III medium supplemented with 10% FBS, 1% penicillin / streptomycin, and mycoeraser at 37°C in 5% CO2.

[0140]

[0141] Test Example 1: Effect on mammary papilla cells

[0142] 1-1: Effect of increasing the diameter of mammary papilla cell spheroids

[0143] Referring to the previous literature [Higgins, CA.et al., Exp Dermatol., 19(6), 546-548, 2010; Higgins, CA.et al., Proc Natl Acad Sci USA., 110(49), 19679-19688, 2013; Kang, BMet al., J Invest Dermatol., 132(1), 237-239, 2012], it was reported that human hair follicle papilla cells cultured as three-dimensional spheroids could induce the formation and growth of hair follicles more than human hair follicle papilla cells cultured on a two-dimensional plane. In addition, the previous literature [Whiting, DA, J Am Acad Dermatol., 45(3 Suppl), S81-S86, 2001; [de Lacharriere, O. et al., Arch Dermatol., 137(5), 641-646, 2001; Jahoda, CA, Exp Dermatol., 7(5), 235-248, 1998] reported that a decrease in the size of the hair papilla can induce hair follicle miniaturization in patients with hair loss. Therefore, the HaCaT_ECM of the example was treated to 3D spheroid-cultured hair papilla cells to confirm the formation and size changes of 3D spheres, thereby confirming the effects of hair loss prevention and hair growth promotion.

[0144] Specifically, human breast papilla cells (HDP cells) were seeded at 5 × 10 in microwell plates (AggreWell, STEMCELL technologies). 3The cells were seeded at a density of 10 cells / microwell and cultured for 24 hours in Prigrow III medium supplemented with 10% FBS, 1% penicillin / streptomycin, and mycoeraser at 37°C and 5% CO2 to form three-dimensional spheroids. Subsequently, the HaCaT_ECM of the example was treated to the microwell plate at an amount of 1 μg / ml, and the diameters of the spheroids were photographed under a microscope on Day 1, Day 3, and Day 7 and measured using analysis software (LAS X, Leica Microsystems) (Figs. 1a and 1b).

[0145] Looking at FIG. 1a and FIG. 1b, it can be confirmed that when the decellularized extracellular matrix derived from skin keratinocytes according to an embodiment of the present invention was treated, the diameter of HDP cells significantly increased compared to the control group, and in particular, it increased to a similar degree to the minoxidil treatment group (10 μM), which is the positive control group.

[0146] 1-2: Effect of increasing genomic DNA in mammary papilla cell spheroids

[0147] In addition, the decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes of the example was treated in an amount of 1 ㎍ / ml to the microwell plate in which the HDP cells were cultured, and on Day 1, Day 3, and Day 7, the spheroids were washed with PBS, and then genomic DNA was extracted using a genomic DNA exraction kit, and the absorbance was measured using a spectrophotometer to measure the amount of genomic DNA in the spheroids (Fig. 1c).

[0148] Looking at Figure 1c, it can be confirmed that when the decellularized extracellular matrix derived from skin keratinocytes according to an embodiment of the present invention was treated, the amount of genomic DNA within the HDP cell spheroids significantly increased compared to the control group.

[0149] 1-3: Effect of increasing the expression of signature genes in mammary papilla cells

[0150] Signature genes expressed in hair papilla cells include ALPL, BMP2, BMP4, CTNNB1, FGF7, HIF1A, LEF1, NOG, SOX2, SPARC, VCAN, WNT5A, WNT10B, and ACTA2, which are significantly increased in expression during 3D culture and are involved in hair growth.

[0151] Specifically, alkaline phosphatase (ALP) is an important protein related to hair follicle induction and growth ability, bone morphogenetic protein 2 (BMP2) and bone morphogenetic protein 4 (BMP4) are essential for dermal papilla cell function, lymphoid enhancer binding factor 1 (LEF1) is involved in promoting dermal papilla cell proliferation, fibroblast growth factor 7 (FGF7) is involved in hair growth, and versican (VCAN) plays an essential role in hair follicle formation. In addition, CTNNB1 is a target gene of β-catenin, and the protein encoded by this gene belongs to the cyclin family and affects the entire cell cycle, and SOX2 is a marker of mesenchymal stem cells, and its expression increases during hair follicle tissue formation (morphogenesis).

[0152] Therefore, in the above Test Example 1-1, human hair follicle papilla cells cultured in a 3D spheroid form were treated with 1 ㎍ / ml of HaCaT_ECM of the example, and then the change in mRNA expression level of the above genes was measured by multiplex RT-PCR using Day7 cell samples to confirm the hair loss prevention and hair growth promotion effects (Fig. 2).

[0153] Looking at FIG. 2, when the decellularized extracellular matrix derived from skin keratinocytes according to an embodiment of the present invention is treated, the mRNA expression levels of ALP, BMP2, HIF1A, BMP4, CTNB1, FGF7, VCAN, and SINT5A are significantly increased compared to the control group, and in particular, the mRNA expression levels of BMP4, CTNB1, FGF7, VCAN, and SINT5A are significantly increased compared to the minoxidil treatment group, which is a positive control group, confirming that the decellularized extracellular matrix derived from skin keratinocytes according to an embodiment of the present invention has excellent hair loss prevention and hair growth promotion effects.

[0154] 1-4: Effect of increasing β-catenin and SOX2 expression

[0155] The decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes of the example was treated at an amount of 1 μg / ml in a microwell plate in which HDP cells were cultured in the form of 3D spheroids, and the Day 7 spheroids were fixed with 4% para-formaldehyde, and then treated with 0.1% Triton X-100 for immunocytochemical analysis, and then treated with 2% normal serum to suppress nonspecific proteins, and then treated with antibodies against β-catenin and SOX2, followed by overnight reaction at 4°C, and then signals were detected with secondary antibodies conjugated with Alexa fluor 488 or Alexa fluor 594, and the nuclei of cells were counterstained with DAPI to confirm (Fig. 3).

[0156] Looking at Figure 3, it can be seen that when HaCaT_ECM of the example was treated, the expression of β-catenin and SOX2 increased compared to the control group (Con), and in particular, the expression of SOX2 increased compared to the positive control group, the minoxidil treatment group (10 μM).

[0157] 1-5: Inhibitory effect on 5α-reductase expression

[0158] The decellularized extracellular matrix (HaCaT_ECM) derived from skin keratinocytes of the example was treated at an amount of 1 μg / ml in a microwell plate cultured with HDP cells in a 3D spheroid shape, and the expression of 5α-reductase involved in androgenetic alopecia was confirmed through immunocytochemical staining on Day 7 (Fig. 4).

[0159] Looking at Figure 4, it can be confirmed that when HaCaT_ECM of the example was treated, the expression of 5α-reductase decreased compared to the control group (Con) and the minoxidil treatment group.

[0160] In addition, HDP cells were cultured and treated with 100 nM dihydrotestosterone (DHT) to prepare an in vitro model for androgenetic alopecia. Then, 1 and 10 μg / ml of decellularized extracellular matrix (HaCaT_ECM) derived from keratinocytes of the example was treated, and on Day 1, the expression of 5α-reductase involved in androgenetic alopecia was confirmed through immunoblotting (Fig. 5). At this time, 200 and 1000 nM of finasteride, an androgen inhibitor, were treated as a positive control.

[0161] To confirm the expression level of 5α-reductase, total protein was extracted using M-PER (Thermo Fisher Scientific, Waltham, USA) extraction solution, and the protein concentration was measured using a protein assay kit (Bio-Rad, Hercules, CA, USA). 20 μg of total protein was separated by SDA-PAGE. EveryBlot Blocking buffer (12010020, Bio-Rad) was used to block background signals, and the sample was reacted with an antibody against 5α-reductase (NBP1-46510, Novusbio). After washing, the sample was reacted with a secondary antibody conjugated with HRP, and the immunoreactive band was detected with a CCD camera using a chemiluminescent substrate.

[0162] Looking at Figure 5, it can be confirmed that when HaCaT_ECM of the example was treated, the expression of 5α-reductase was reduced compared to the finasteride treatment group.

[0163] The above results suggest that the HaCaT_ECM of the present invention is effective in preventing, improving, or treating male pattern baldness by reducing the expression of an enzyme (5α-reductase) that produces a causative agent of androgenetic alopecia (male pattern baldness).

[0164]

[0165] Test Example 2: Effect on hair root cells

[0166] 2-1: Cell proliferation effect

[0167] 5 × 10 hair root sheath cells (ORS cells) were seeded in a 96-well plate. 3 The ORS cells were seeded at a density of 10 cells / well and cultured for 24 hours under Dermalife basic medium (Lifeline cell technology, LM-0004) supplemented with mycoeraser and growth factors (Lifeline cell technology, LS-1030) at 37°C and 5% CO2. Afterwards, the plates were treated with the HaCaT_ECM of the example at an amount of 0.05 μg / ml and 0.1 μg / ml, and as a positive control, Minoxidil was treated at an amount of 1 μM and 10 μM. Then, CCK-8 solution (Dojindo, CK04) was added at a concentration of 10% on Day 0, Day 1, Day 3, and Day 5, and the absorbance at a wavelength of 450 nm was measured after 1 to 4 hours to compare the cell proliferation of the ORS cells (Fig. 5).

[0168] Looking at Figure 5, it can be confirmed that when HaCaT_ECM of the example was treated, the proliferation of ORS cells significantly increased compared to the control group.

[0169] These results suggest that the HaCaT_ECM of the present invention can activate the proliferation of hair root sheath cells.

[0170] 2-2: Effect of increasing ALP expression

[0171] After treating the plate on which ORS cells were cultured with HaCaT_ECM of the example at 1 ㎍ / ml, the expression of ALP, which is involved in cell proliferation and hair cycle regulation, was confirmed by immunocytochemical staining on Day 7 (Fig. 6a).

[0172] Looking at Fig. 6a, it can be confirmed that when HaCaT_ECM of the example was treated, the expression of ALP increased compared to the control group.

[0173] 2-3: Effect of increasing Sox9 expression

[0174] After treating the HaCaT_ECM of the example at 1 ㎍ / ml on a plate cultured with ORS cells, the expression of Sox9, which is involved in hair cycle regulation and hair follicle stem cell formation, was confirmed by immunocytochemical staining on Day 7 (Fig. 6b).

[0175] Looking at Figure 6b, it can be confirmed that when HaCaT_ECM of the example was treated, the expression of Sox9 increased compared to the control group.

[0176] 2-4: Effect of increasing β-catenin expression

[0177] After treating the HaCaT_ECM of the example at 1 ㎍ / ml on a plate cultured with ORS cells, the expression of β-catenin, which is involved in hair cycle regulation and hair follicle formation, was confirmed by immunocytochemical staining on Day 7 (Fig. 6c).

[0178] Looking at Figure 6c, it can be confirmed that the expression of β-catenin increased when HaCaT_ECM of the example was treated compared to the control group.

[0179]

[0180] Test Example 3: Comparison of efficacy with extracellular matrices derived from other cells

[0181] The efficacy of HaCaT_ECM of the example on hair papilla cells was compared with that of dermal fibroblast-derived extracellular matrix (HDF_ECM).

[0182] 3-1: Preparation of skin fibroblast-derived extracellular matrix (HDF_ECM)

[0183] The same procedure as in the example was followed, but decellularized extracellular matrix (HDF_ECM) was prepared using skin fibroblasts (HDF cells) instead of skin keratinocytes (HaCaT cells).

[0184] 3-2: Cell Scratch Analysis (Skin Regeneration Effect)

[0185] After treating HDF (human dermal fibroblast) with MMC to limit the cell proliferation ability and scratching it, HaCaT_ECM and HDF_ECM were treated respectively, and the cell migration ability over time was compared.

[0186] Specifically, HDF cells were seeded at 2.5E+05 cells / well in 6-well plates (30006, SPL) and cultured to approximately 100% confluency. Once the cells reached confluency, they were treated with 1 ml / well of Mitomycin C (M4287, Sigma-Aldrich) diluted to 10 µg / ml in DMEM high glucose (D6429, sigma) without FBS supplemented with 1% penicillin streptomycin (1514-163, gibco). After culturing for 2 hours, the cells were washed with DPBS, and the cells were scraped vertically from the well using a 1000 µl pipet tip. Cell debris was removed by washing with DPBS, and HaCaT_ECM and HDF_ECM were each treated with DMEM high SFM at 10 ng / ml. After HaCaT_ECM and HDF_ECM treatment, photographs were taken at fixed locations at 0, 6, 18, 24, and 48 hours to determine the extent of cell migration. The extent of migration was analyzed and compared using TScratch software (Fig. 7).

[0187] Looking at Figure 7, it can be confirmed that the movement ability of HDF treated with HaCaT_ECM is higher than that of the Control and HDF_ECM treated groups.

[0188] 3-3: Effect of increasing growth factor mRNA and protein expression

[0189] After treating HDF (human dermal fibroblast) with HaCaT_ECM and HDF_ECM at 10 nm / ml each, multiplex RT-PCR was performed. As a result, it was confirmed that FGF2, TGFB2, and COL3A1 mRNA expression in HDF treated with HaCaT_ECM was significantly increased compared to the control and HDF_ECM treated groups (Fig. 8).

[0190] In addition, when human growth factor antibody array membrane was performed after treating HDF (human dermal fibroblast) with HaCaT_ECM and HDF_ECM at 10 nm / ml each, it was confirmed that the expression of growth factor proteins such as bNGF and PDGF-BB in HDF treated with HaCaT_ECM increased compared to the control and HDF_ECM treated groups (Fig. 9).

[0191] 3-4: Effect of increasing the expression of signature genes in mammary papilla cells

[0192] In the above Test Example 1-1, human hair follicle papilla cells cultured in the form of 3D spheroids were treated with HaCaT_ECM and HDF_ECM at 10 nm / ml each, and multiplex RT-PCR was performed. As a result, it was confirmed that the mRNA expression of ALP, BMP2, BMP4, CTNB1, HIF1A, NOG, SPARC, VCAN, WNT5A, WNT10B, and ACTA2, which are signature genes of hair follicle papilla cells, in HDF treated with HaCaT_ECM significantly increased compared to the control and HDF_ECM treated groups (Fig. 10).

[0193]

[0194] Test Example 4: Evaluation of hair growth improvement efficacy in animal experiments

[0195] In order to verify the hair growth or hair growth improvement efficacy of HaCaT_ECM of the example, an experiment was conducted using mice whose hair cycles were synchronized using an electric hair remover and hair removal cream.

[0196] Specifically, male C57Bl / 6 mice were acclimated to the breeding facility for a week, and the condition of the experimental animals was optimally maintained in each cage until the start of the experiment. Thereafter, the hair on the back of the mice was removed with an electric depilator, and the surrounding fine hair was completely removed using a hair removal cream. The hair growth improvement efficacy of the ECM test group in which 0.1 wt% of the HaCaT_ECM of the example was applied to the back skin of the mice and the positive control group (3% minoxidil) in which minoxidil was applied was evaluated (Fig. 11). Specifically, FIG. 11a is a photograph showing the degree of hair growth on Day 0, Day 5, Day 7, and Day 14 after the decellularized extracellular matrix (HaCaT_ECM) of the present invention was treated on the back skin of the mouse after hair removal, compared to the minoxidil treatment group, which is a positive control group, and FIG. 11b is a microscopic observation result showing that no side effect of hyperkeratosis of the back skin of the mouse on Day 14 was observed, and FIG. 11c is a graph showing the number of hair follicles corresponding to each hair cycle for tissues collected from the back skin of the mouse on Day 14.

[0197] Looking at Figure 11, it can be confirmed that when HaCaT_ECM of the example is treated in a mouse model with synchronized hair cycle, hair growth efficacy similar to that of the positive control group is shown and no skin hyperkeratosis side effect appears.

[0198] Through this, it can be seen that the HaCaT_ECM of the present invention has excellent hair growth or hair growth promotion efficacy.

[0199]

[0200] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A cosmetic composition for preventing or improving hair loss, or promoting hair growth or hair growth, containing a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

2. In paragraph 1, A cosmetic composition characterized in that the above decellularized extracellular matrix is ​​obtained from cells cultured in vitro.

3. In paragraph 1, A cosmetic composition characterized in that the above decellularized extracellular matrix activates dermal papilla cells (DPCs) to induce hair growth.

4. In paragraph 1, A cosmetic composition characterized in that the above cosmetic composition comprises 0.001 to 10.0 (w / v)% of the decellularized cells and extracellular matrix.

5. In paragraph 1, A cosmetic composition characterized in that the above cosmetic composition has a formulation of hair tonic, hair lotion, hair oil, hair shampoo, hair rinse, hair conditioner, hair treatment, hair cream, hair pack, hair spray, hair essence, hair mousse or hair gel.

6. A pharmaceutical composition for preventing or treating hair loss, or for promoting hair growth or hair growth, comprising a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

7. In paragraph 6, A pharmaceutical composition characterized in that the above pharmaceutical composition has a formulation of an injection, infusion, spray, liquid or patch.

8. In paragraph 6, A pharmaceutical composition characterized in that the pharmaceutical composition is administered transdermally by topical application to the scalp of a mammal, microneedling, injection, or a combination thereof.

9. A pharmaceutical composition for preventing or improving hair loss, or promoting hair growth or hair growth, containing a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

10. A health functional food composition for preventing or improving hair loss, or promoting hair growth or hair growth, containing a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an active ingredient.

11. A feed composition for preventing or improving hair loss, or promoting hair growth or hair growth, containing a decellularized extracellular matrix (ECM) derived from skin keratinocytes as an effective ingredient.

Citation Information

Patent Citations

  • Composition for sustained release of bioactive subastances comprising a decellularized extracellular matrix and use thereof

    KR1020160126766A

  • Decellularized extracellular matrix of conditioned body tissues and uses thereof

    US20090138074A1

  • Systems, compositions and methods for the treatment of alopecia

    WO2014047246A1

Cited By

  • Preparation method and application of extracellular matrix based on human skin organoid

    CN121648342A